From feedback loop transitions to biomarkers in the psycho-immune-neuroendocrine network:Detecting the critical transition from health to major depression by Stapelberg, N J C et al.
Bond University
Research Repository
From feedback loop transitions to biomarkers in the psycho-immune-neuroendocrine network
Stapelberg, N J C; Pratt, R; Neumann, D L; Shum, D H K; Brandis, S; Muthukkumarasamy, V;
Stantic, B; Blumenstein, M; Headrick, J P
Published in:
Neuroscience and Biobehavioral Reviews
DOI:
10.1016/j.neubiorev.2018.03.005
Published: 01/07/2018
Document Version:
Peer reviewed version
Link to publication in Bond University research repository.
Recommended citation(APA):
Stapelberg, N. J. C., Pratt, R., Neumann, D. L., Shum, D. H. K., Brandis, S., Muthukkumarasamy, V., ...
Headrick, J. P. (2018). From feedback loop transitions to biomarkers in the psycho-immune-neuroendocrine
network: Detecting the critical transition from health to major depression. Neuroscience and Biobehavioral
Reviews, 90, 1-15. https://doi.org/10.1016/j.neubiorev.2018.03.005
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
 1 
From Feedback Loop Transitions to Biomarkers in the Psycho-Immune-
Neuroendocrine Network: Detecting the Critical Transition from Health to Major 
Depression  
 
N.J.C. Stapelberg, R. Pratt, D.L. Neumann, D.H.K. Shum, S. Brandis, V. 
Muthukkumarasamy, B. Stantic, M. Blumenstein, J.P. Headrick 
 
 
Short title: Feedback Loop Transitions in the PINE Network 
 
 
Professor Nicolas J.C. Stapelberg (Corresponding Author) 
BSc Hons, MBBS, PhD, FRANZCP,  
Bond University Faculty of Health Sciences and Medicine and Gold Coast Hospital and 
Health Services 
14 University Dr, Robina, Queensland 4226, Australia.  
Email: cstapelb@bond.edu.au 
No conflicts of interest 
 
Dr Robin Pratt 
MB ChB FRCPA MBA AMInstD 
Gold Coast University Hospital  
Gold Coast, QLD, Australia 
E-mail: robin.pratt@health.nsw.gov.au 
 
No conflicts of interest 
 
Professor David L. Neumann  
BSc Hons, GCert HigherEd, PhD  
 2 
School of Applied Psychology,  
Griffith University, Gold Coast, QLD, Australia  
Email: d.neumann@griffith.edu.au 
No conflicts of interest 
 
David H. K. Shum  
BA Hons, PhD, FAPS, FASSBI  
School of Applied Psychology,  
Griffith University, Gold Coast, QLD, Australia 
Neuropsychology and Applied Cognitive Neuroscience Laboratory, CAS Key Laboratory of 
Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China  
Email: D.Shum@griffith.edu.au 
No conflicts of interest 
 
 
Professor Susan Brandis  
F.C.H.S.E., B.Occ.Thy., B. Bus. (Health Admin), C.H.E.,  
Faculty of Health Sciences and Medicine 
Bond University QLD 4229, Australia 
Email: sbrandis@bond.edu.au 
No conflicts of interest 
 
Associate Professor Vallipuram Muthukkumarasamy 
BScEng (Peradeniya), PhD (Cambridge), MIEEE, MIET 
School of Information and Communication Technology,  
 3 
Griffith University, Gold Coast, QLD 4222, Australia 
Email: v.muthu@griffith.edu.au 
No conflicts of interest 
 
Professor Bela Stantic 
School of Information and Communication Technology,  
Griffith University, Gold Coast, QLD 4222, Australia 
Email: b.stantic@griffith.edu.au 
No conflicts of interest 
 
Professor Michael Blumenstein 
BSc (Comp), BIT (Hons), PhD, FACS SMIEE  
Faculty of Engineering and Information Technology  
University of Technology Sydney  
NSW 2007 
Email: Michael.Blumenstein@uts.edu.au 
No conflicts of interest 
 
Professor John P. Headrick  
BSc. Hons, PhD. 
School of Medical Science,  
Griffith University, Gold Coast, QLD 4222, Australia  
Email: j.headrick@griffith.edu.au  
No conflicts of interest 
 
 
Funding: This research is supported by a Gold Coast Hospital and Health Service Private 
Practice Trust Fund Grant (PPTF-132-17.12.15) 
 
 4 
 
Key words: Major Depressive Disorder, Critical Transition, Feedback Loop Transition 
Biomarker, Psycho-Immune-Neuroendocrine Network, Feedback Loop, Network Motif 
 
 
10490 Words 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Abstract 
Background 
Biological pathways underlying major depressive disorder (MDD) can be viewed as systems 
biology networks. The psycho-immune-neuroendocrine (PINE) network comprises central 
nervous, immune, endocrine and autonomic systems, integrating biological mechanisms of 
MDD. Such networks exhibit recurrent motifs with specific functions, including positive and 
negative feedback loops, and are subject to critical transitions, influenced by feedback loop 
transitions (FLTs).  
Aims 
We aim to identify critical feedback loops and their FLTs, as well sentinel network nodes 
(SNNs), key network nodes that drive FLTs, within the PINE network. Examples of 
biomarkers are provided which may reflect early warning signs of impending critical 
transition to MDD.  
Results 
Disruption of homeostatic feedback loops reflects the physiological transition to MDD. 
Putative FLTs are identified within hypothalamic-pituitary-adrenal (HPA) and sympathetic-
parasympathetic axes, the kynurenine pathway, gut function and dysbiosis.  
Conclusions 
Progression from health to disease is driven by FLTs in the PINE network, which is likely to 
undergo changes characteristic of system instability. Biomarkers of system instability may 
effectively predict the critical transition to MDD. 
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1. Introduction 
1.1 Major Depression in the Context of Systems Biology and Biological Networks 
Major Depressive Disorder (MDD) is recognised as one of the most common and 
debilitating diseases worldwide (Belmaker & Agam, 2008; Charlson, Stapelberg, Baxter, & 
Whiteford, 2011). The lifetime prevalence of MDD is approximately 17% within the 
population globally, underpinning tremendous secondary costs to society (Kessler, Chiu, 
Demler, & Walters, 2005; Wang, Simon, & Kessler, 2003). MDD is one of the largest causes 
of morbidity worldwide (Vos & Mathers, 2000) and is currently ranked third in terms of 
global burden of disease  (World Health Organization, 2008). It is the leading cause of 
neuro–psychiatric disability (Lopez & Mathers, 2006) and has been predicted to be among 
the three leading causes of burden of disease worldwide by 2030 (Mathers & Loncar, 2006).  
There is a growing body of research into the biological pathways that mechanistically 
underlie MDD. In recent years these paths have increasingly been viewed as biological 
networks (Headrick et al., 2017; Stapelberg, Neumann, Shum, McConnell, & Hamilton-
Craig, 2011; Stapelberg, Neumann, Shum, McConnell, & Hamilton-Craig, 2015; Sterling & 
Eyer, 1988). Stapelberg et al. (2015) proposed the psycho-immune-neuroendocrine (PINE) 
network model to better understand and integrate putative biological mechanisms for MDD, 
and also how MDD is related to other general medical conditions. The PINE network model 
is comprised of central nervous system (CNS), immune, endocrine and autonomic networks. 
These constituent networks have been previously described individually or in combination. 
For example, networks modulating immune, autonomic and endocrine functions have been 
described as the neuroendocrine-immune network (Freier, 1990), the immune-
neuroendocrine network (INEN) (Correa et al., 2007), or the neuroendocrine-immune axis 
(Homo-Delarche & Dardenne, 1993). The integrative term "psycho-neuroimmunology" has 
also been used to describe the study of biological mechanisms which underlie behavior and 
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mood in MDD (Ader, 2000).  
The recognition of networks in biology and adoption of systems biology approaches 
have become widespread, and are pertinent to the study of MDD. Many fields of biology 
increasingly employ high-throughput experimental methods to generate greatly increased 
volumes of experimental data that are inherently complex and interconnected (Gehlenborg et 
al., 2010). The inter-connectedness of complex biological interactions has driven a paradigm 
shift from reductionist methodologies to the more holistic and inclusive paradigm of systems 
biology: the integrated and holistic analysis of complex interacting biological pathways or 
networks (Kirschner, 2005; Noorbakhsh, Overall, & Power, 2009). Emerging fields of high-
throughput, data-rich biology, which employ systems biology and network approaches, have 
become identified by the suffix “ome” or “omics”. Familiar fields of research in this area 
include genomics, proteomics and metabolomics (Hogenesch & Ueda, 2011).  
An important characteristic of biological networks is their ability to maintain their 
stability, in other words their propensity to self-regulate or maintain homeostasis (Bashan, 
Bartsch, Kantelhardt, Havlin, & Ivanov, 2012; Stapelberg et al., 2015; Sterling & Eyer, 
1988). Systems biology aims to construct coherent models that predict how biological 
systems might respond to different perturbations (Gracey, 2007). An important element of 
complex biological system responses to perturbation is the feedback loop (Kitano, 2004). 
Complex biological networks have recurrent structures, which achieve specific regulatory or 
other functions. Structures such as positive and negative feed-forward and feed-back loops 
are recognizable across different biological (and other) networks, and are known as ‘network 
motifs’ (e.g. Alon, 2007; Milo et al., 2002; Prill, Iglesias, & Levchenko, 2005). Negative 
feedback is more common and widespread in biology than positive feedback. Negative 
feedback broadly acts to stabilize, whereas positive feedback amplifies system perturbations 
and triggers changes in state, which may lead to system instability. Dysfunction within 
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negative feedback loops can impair homeostasis, while transition from negative to positive 
feedback may induce profound changes in the state of the system.  
 
1.2 Feedback Loops, Sentinel Network Nodes and Critical Transitions in the Psycho-
Immune-Neuroendocrine Network 
It has previously been argued that the complex network of physiology underlying 
MDD undergoes a critical transition from a healthy PINE physiome to a PINE pathome with 
the onset of MDD (Stapelberg et al., 2015). The physiology underlying MDD consists of 
multiple interlocking pathways (e.g. see Stapelberg et al., 2011; Stapelberg et al., 2015, 
Headrick et al., 2017) and we assert here that the complex physiology underlying critical 
transition to MDD involves multiple feedback loop transitions (FLTs) from negative to 
positive feedback. We propose that these FLTs destabilise the PINE network, creating an 
unstable pre-disease state which can be measured using biomarkers, and that the FLTs of 
multiple physiological regulatory loops leads to positive feedback loop dominance and 
critical transition of the PINE network to the pathological state of MDD.  
Critical transitions are defined as the thresholds at which entire systems shift abruptly 
from one state to another (Scheffer et al., 2009) and complex systems exhibit tipping points at 
which minor perturbations can invoke critical transition to a new stable state (Veraart et al., 
2012). While critical transitions generally occur at a ‘whole-of-system’ level, they are 
brought about by changes within constituent regulatory elements of that system (Kitano, 
2004; Veraart et al., 2012). It has been put forward that disease manifests from a gradual 
deterioration of health (which is frequently reversible), through relatively sudden critical 
transitions that demark a definitive disease onset and are frequently irreversible (Chen, Liu, 
Li, & Chen, 2016; Li, Jin, Lei, Pan, & Zou, 2015).  
The concept of critical transitions is related to network motifs and feedback 
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mechanisms within complex systems, including biological systems (e.g. An, Nieman, & 
Vodovotz, 2012). Critical transitions in complex systems are influenced by transitions in 
constituent feedback loops and shifts in dominance between negative vs. positive loops, a 
concept known as 'loop dominance' (Ford, 1999; Sterman, 2000). The relationships between 
systems, comprised of feedback loops, loop dominance and critical transition of a system are 
illustrated in Figure 1. One challenge in establishing detailed models of feedback loop 
dominance to describe system behaviour has been in defining loop dominance itself; and 
therefore establishing what makes a particular feedback loop dominant (Ford, 1999). One 
definition of loop dominance posits that "a loop that is primarily responsible for model 
behaviour over some time interval is known as a dominant loop." (Richardson & Pugh III, 
1981, p 285).  
System dynamics explains how the structure or architecture of a system drives its 
behaviour (Ford, 1999). This concept is related to the idea that the existence of structural and 
dynamic properties of systems are largely independent of the detailed individual pathways or 
mechanistic components constructing the system (e.g. Mikulecky, 2001) - that is, they have 
emergent properties. Describing and linking feedback loops and shifts in loop dominance 
within a system to behaviour patterns, especially critical transitions, is vital in understanding 
system behaviour, and requires analysis to identify dominant loops in the system (Ford, 
1999). Indeed, a key goal of system dynamics is understanding how the feedback structure of 
a system contributes to its dynamic behaviour (Richardson, 1995).  
The concept of critical transitions in physiological systems is illustrated briefly by the 
well-studied mechanisms of insulin resistance. A negative feedback loop, such as that 
governing homeostatic control of blood glucose levels, can be gradually disrupted by 
increasing resistance to insulin. Insulin resistance itself is complex and can be caused by 
numerous defects in the insulin signaling cascade (e.g. Kadowaki et al., 2006), although 
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disruption to glucose homeostasis can be illustrated in relatively simple terms. Increased 
blood glucose triggers insulin secretion by pancreatic ß-cells, and insulin signaling 
mechanisms cause glucose to be transported into cells, lowering blood levels. Insulin 
resistance causes less glucose to be transported into cells, which drives increased insulin 
production. While there is still an inhibitory effect from insulin, this diminishes with 
increasing insulin resistance. There is a point at which the net inhibitory effect reaches zero, 
which represents the FLT of this system. From here, the system enters into a positive 
feedback loop with more insulin being produced, driving further insulin resistance and 
elevation of blood glucose. This is a relatively simple example, and it should be recognised 
that the insulin system is interleaved with other physiological systems, forming a complex 
network (e.g. Taniguchi, Emanuelli, & Kahn, 2006). 
PINE physiology is viewed as a network, constituted of nodes and edges. Nodes can 
be genes, proteins or biochemical and physiological processes that are connected to multiple 
other system elements via edges (e.g. McNally, 2016). Nodes with greater numbers of 
connections have greater regulatory potential, while other nodes can serve as control 
elements in physiological feedback loops regardless of their interconnectivity. Taniguchi et 
al. (2006) defined ‘critical nodes’ in signalling networks that are essential for a receptor-
mediated signal, have unique biological roles within a signalling network, are highly 
regulated (positively and negatively), and form one or more junctions for potential crosstalk 
with other signalling systems. Transitions around such nodes will have profound and system-
wide effects on the transition from health to disease. Wittenborn, Rahmandad, Rick, and 
Hosseinichimeh (2016) identified ‘candidate stock variables’ that they identified as 
regulating the strength and dynamics of the reinforcing loops they describe. We also seek to 
identify nodes that are critical to FLTs in the described regulatory loops. These may not meet 
the criteria for ‘critical nodes’ as defined by Taniguchi et al. (2006), but represent nodes that 
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are likely to directly drive FLTs (thus ultimately contributing to system-wide transitions) and 
we have named these sentinel network nodes (SNNs). 
The first aim of this paper is to identify important feedback loops in the PINE 
network based on current knowledge. Negative and positive feedback loops within the PINE 
physiome are defined, and it will be shown how loss of negative feedback and creation of 
positive feedback - evolution of a FLT - can lead to positive feedback loop dominance in the 
PINE network and thereby drive critical transition to MDD. We propose that by monitoring 
shifts in feedback loop dominance with biomarkers designed to detect early warning signs of 
critical transitions (Scheffer et al., 2009), particularly around SNNs, a global transition to 
MDD might be detectable and indeed predictable. We outline examples of measurable 
biomarkers related to critical transition of the PINE network, based on shifts in the behaviour 
of feedback loops. These biomarkers are hypothesized to predict how patterns of critical 
transition will collectively change between healthy individuals and people with MDD, and 
how they may therefore serve as a screening tool for the onset of MDD. One example is 
provided for each early warning sign of critical transition, as proposed by Scheffer et al. 
(2009). 
Biomarkers can be defined as specific biological features, or any substance, structure, 
or process that can be measured in the body to aid in distinguishing the presence or absence 
of a specific disease (Schmidt, Shelton, & Duman, 2011; Strimbu & Tavel, 2010). While 
there have been advances in the study of biomarkers in MDD, efforts to validate MDD 
biomarkers have been challenging and a quantitative clinical test for MDD remains elusive 
(Kennedy et al., 2012; Lakhan, Vieira, & Hamlat, 2010). Clinical utility is governed by 
multiple factors, notably their mechanistic linkage to MDD pathology (which may be 
difficult to elucidate), sensitivity and specificity relative to other psychological disorders, and 
dependence on complicating factors such as sex, age, diet and activity. Pathological 
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heterogeneity evident in MDD also remains a critical factor limiting the applicability of 
biomarkers, while technical and economic factors or constraints are important in determining 
broader utility. Additional to blood and cerebrospinal fluid (CSF) biomarkers, and genomic, 
transcriptomic, proteomic and metabolomic analytical approaches, modalities such as 
neuroimaging and electroencephalographic (EEG) analyses offer some potential. For 
example, shifts in EEG patterns are evident in depression, however despite recent 
encouraging reports (e.g. Lee, Kan, Croarkin, Phang, & Doruk, 2018) there remains 
significant heterogeneity in findings (in part reflecting pathological heterogeneity), and 
broader utility in MDD remains to be established. Despite considerable research and testing 
there is no consensus on which biomarkers are sufficiently sensitive and specific to be 
employed clinically.  
In recent times there has been recognition of the importance of examining groups or 
panels of biomarkers, rather than investigating individual markers, in relation to chronic 
stress (Juster, McEwen, & Lupien, 2010) or MDD (Domenici et al., 2010; Strawbridge, 
Young, & Cleare, 2017). It has been recommended that large groups of biomarkers across 
different modalities be studied in concert, and that advanced mathematical modelling, 
machine learning and pattern recognition methods be used to analyze such biomarker 
groupings and their relation to diseases such as MDD (Kennedy et al., 2012; McEwen, 2015). 
Groups of markers of feedback loop behaviour, e.g. shifts in feedback loop dominance, may 
cumulatively offer a unique capacity to monitor the emergence of unstable pre-disease states, 
or presage a critical transition. We highlight biomarkers directly linked to disease 
mechanism, based on connections and mechanisms within the theoretical PINE network 
(Stapelberg et al., 2015).  
There is a wider literature examining networks in the context of MDD. For example 
Borsboom and Cramer (2013), provide a network analysis of symptoms of MDD and 
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generalized anxiety disorder (GAD) based on the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) and correlations based on National 
Comorbidity Survey Replication data. Wittenborn et al. (2016) present networks that 
combine psychological, cognitive, social and biological factors. While they identify 
reinforcing and negative feedback in their models, the concept of feedback loop transitions 
are not described. While these examples illustrate that network models of MDD can 
incorporate a wide range of nodes related to psychological symptoms or social factors, we 
have restricted this paper to physiological mechanisms only. 
 
2. Results 
2.1 Endocrine-Related Feedback Loops: Glucocorticoid Receptors, the Glucocorticoid 
Negative Feedback Loop and Glucocorticoid Resistance in Major Depression 
The hypothalamic pituitary adrenal (HPA) axis is a well-studied regulatory system 
that is crucial to energy regulation in the body to meet metabolic demand, through control of 
glucose availability among other mechanisms (Pecoraro et al., 2006). It is also intimately 
involved in the response to stress (Stapelberg et al., 2015), and feedback mechanisms exist at 
multiple levels. The principal HPA axis pathway starts with the hypothalamus in the central 
nervous system (CNS) and ends with the secretion of glucocorticoids such as cortisol into the 
bloodstream, a pathway subject to negative feedback control and which can be viewed as 
cyclical in that it is self-regulating (Figure 2A).  
[Figure 2A could be placed here] 
The synthesizing motor neurons of the paraventricularnucleus (PVN) in the 
hypothalamus release corticotropin-releasing hormone (CRH) into the portal vasculature of 
the median eminence (Fink, 2010; Pecoraro et al., 2006). CRH stimulates adrenocorticotropic 
hormone (ACTH) production in the glandular corticotrope cells of the anterior pituitary 
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gland, and its release into the bloodstream (Pecoraro et al., 2006). Circulating ACTH 
stimulates the production of glucocorticoids (e.g. cortisol) in the adrenal cortex, which enter 
the systemic circulation and can cross the blood brain barrier to act in the CNS. 
Glucocorticoids act by binding to glucocorticoid receptors (GRs) in target tissues, including 
the hypothalamus. GRs in the hypothalamus trigger a reduction of CRH production and 
secretion, which negatively feeds back on the HPA axis pathway, ultimately slowing the 
production of cortisol and other glucocorticoids (e.g. O'connor, O'halloran, & Shanahan, 
2000; Tsigos & Chrousos, 2002). In addition, glucocorticoids themselves inhibit both the 
synthesis and release of ACTH (Axelrod & Reisine, 1984). 
 However, the feedback loops that involve GRs are more complex, since 
glucocorticoids also bind to mineralocorticoid receptors (MR). The MRs are expressed in the 
kidneys, heart and intestine, and also in limbic brain regions including the hippocampus. 
They have a higher affinity for glucocorticoids than GRs (Rupprecht et al., 1993) and are thus 
more completely occupied by basal levels of corticosteroid secretion under normal 
physiological conditions (Anacker, Zunszain, Carvalho, & Pariante, 2011a). Conversely, 
relatively low affinity GRs (Rupprecht et al., 1993) require high glucocorticoid 
concentrations for full activation and subsequent dampening of HPA axis activity. Both MRs 
and GRs are required to drive the HPA axis negative feedback loop, thus the ratio of MR/GR 
expression and activation is important in MDD (Juruena et al., 2006). Under normal 
physiological conditions, the MR/GR activity ratio is high since MRs are more fully occupied 
than GRs (Anacker et al., 2011a). Indeed, it has even been suggested MR activation alone 
may largely account for behavioral reactivity to acute and brief stressors (Holsboer, 2000). 
However chronic stress, which can lead to MDD, causes a sustained elevation in 
glucocorticoid production, and thus more complete GR binding and a reduced MR/GR ratio 
(Holsboer, 2000). Importantly, the effects of combined MR and GR activation with chronic 
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stress and glucocorticoid release are distinct from those of GR or MR activation alone 
(Anacker et al., 2013a), and may be maladaptive, for example inhibiting neurogenesis. 
Chronically elevated glucocorticoids also induce initial MR desensitization and subsequent 
GR desensitization and glucocorticoid resistance (Holsboer, 2000; Pace, Hu, & Miller, 2007; 
Tsigos & Chrousos, 2002). Glucocorticoid resistance is in effect a reduced response to 
increased ligand levels, involving mechanisms which inhibit glucocorticoid bioavailability, 
GR expression and signaling, thereby suppressing negative feedback effects previously 
driven by GR activity.  
With loss of the negative feedback loop that normally regulates glucocorticoid serum 
concentrations, glucocorticoid levels continue to rise with no corresponding dampening of 
the immune response or de-activation of the HPA axis. This is illustrated in Figure 2B. A 
regulatory negative feedback loop is thus transitioned to a positive (or feedforward) loop, 
dysregulating the physiological cycle to promote pathology. Glucocorticoid and thus HPA 
axis dysregulation is implicated in several pathways which lead to MDD, particularly 
immuno-inflammatory paths.  
[Figure 2B could be placed here] 
 
2.1.1 Mechanisms of Glucocorticoid Resistance - Limitation of Glucocorticoid 
Availability 
Three mechanisms determining the intracellular availability of glucocorticoids are 
implicated in glucocorticoid resistance. The first involves multidrug resistance P-
glycoprotein (MDR), which acts as an efflux pump, removing intracellular toxins in organs 
including the adrenal glands, kidneys, liver, gut, and brain. The MDRs in the blood-brain 
barrier endothelium extrude cortisol and other glucocorticoids from these cells, effectively 
limiting cortisol availability at intracellular GRs (Silverman & Sternberg, 2008). Acute 
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inflammatory responses down-regulate MDR function, increasing the availability of 
glucocorticoids and thereby permitting the feedback dampening of inflammation. Conversely, 
chronic inflammation results in up-regulation of MDR expression, limiting cortisol 
availability and contributing to cortisol resistance (Silverman & Sternberg, 2008).  
The second mechanism relates to corticosteroid binding globulin (CBG), which binds 
~90% of circulating glucocorticoids. Enhanced CBG expression thus limits glucocorticoid 
bio-availability, restricting movement from capillaries into cells and potentially contributing 
to glucocorticoid resistance (Silverman & Sternberg, 2008). Pro-inflammatory cytokines 
(particularly IL-6) reduce CBG expression, increasing glucocorticoid availability and thus 
dampening inflammation (Silverman & Sternberg, 2008). However it has been argued that in 
chronic inflammation changes in CBG expression may reduce glucocorticoid availability 
(Silverman & Sternberg, 2008, 2012). 
The third mechanism implicates the two isoforms of 11β-hydroxysteroid 
dehydrogenase (11β-HSD) in glucocorticoid resistance. The 11β-HSD-1 isoform converts 
glucocorticoids to their biologically active form, while 11β-HSD-2 converts them to 
intermediate inactive forms (e.g. cortisol to cortisone). In an acute inflammatory response, 
pro-inflammatory cytokines such as TNF-α and IL-1β promote 11β-HSD-1 up-regulation 
and 11β-HSD-2 down-regulation in several cell types, favouring active glucocorticoid 
signalling and negative feedback that subsequently dampens inflammation (Figure 2A). 
However it has been proposed that in chronic inflammation, the levels of both 11β-HSD 
isoforms may be altered to increase inactive relative to active glucocorticoids, for example by 
increasing 11β-HSD-2 conversion to inactive forms which do not trigger a dampening of 
inflammation, thus limiting availability of active glucocorticoids and thus contributing to 
glucocorticoid resistance (Silverman & Sternberg, 2008, 2012). 
 
 17 
2.1.2 The HPA Axis and Immune Regulation: Glucocorticoid Receptors and Nuclear 
Factor Kappa-B in Immune-Related Feedback Loops 
The balance between glucocorticoid and nuclear factor kappa-B (NF-κB) signaling is 
an additional and important mechanism influencing glucocorticoid resistance (reviewed in 
McKay & Cidlowski, 1999), linked to immuno-regulatory negative feedback control. The 
immune system can defend the body from infection by maintaining a dynamic balance 
between pro-inflammatory (e.g IL-1, IL-2, IL-6, and TNF-α) and anti-inflammatory 
mediators (e.g. IL-4, IL-10 and IL-13). This balance shifts towards a pro-inflammatory state 
when the immune system is challenged, while regulatory mechanisms appropriately dampen 
this response to limit damage to the body (Eskandari & Sternberg, 2002; Olofsson, Rosas-
Ballina, Levine, & Tracey, 2012). The balance between pro- and anti-inflammatory cytokines 
is regulated in part by the HPA axis. Pro-inflammatory cytokines such as IL-6 stimulate the 
HPA axis and CRH, in particular via the hypothalamus and the amygdala (Besedovsky & 
Rey, 1996; Raison, Capuron, & Miller, 2006), driving glucocorticoid release. Glucocorticoids 
in turn feedback on the immune system to inhibit pro- and promote anti-inflammatory 
cytokine production, including annexin-1, SLPI, IL-10 and the NF-κB inhibitor IκB-α, 
though these may be differentially expressed in different cell types (Barnes, 2006). These 
actions create a regulatory negative feedback loop to dampen inflammation. GRs and NF-κB 
are central to this immune regulatory feedback loop, which in turn influences glucocorticoid 
resistance. 
GRs and NF-κB are inducible transcription factors with opposed functions in immune 
and inflammatory control. The master regulator NF-κB, together with pro-inflammatory 
transcription factors such as activator protein-1 (AP-1), mediate pro-inflammatory cytokine 
production (Barnes, 2006; McKay & Cidlowski, 1999). GRs function as ligand-dependent 
transcription factors to down-regulate cytokine gene expression: GR binding at 
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glucocorticoid response elements (GREs) in promoter regions of corticosteroid-responsive 
genes can both suppress transcription of (transrepress) inflammatory system elements, 
including cytokines (IL-12, TNF-α, interferon-γ), adhesion molecules and inflammatory 
enzymes, and promote transcription of (transactivate) anti-inflammatory mediators such as 
IL-10 (Barnes, 2006; Sternberg, 1997). These regulatory actions may be influenced by 
physical interaction between GRs and NF-κB, which function as mutual transcriptional 
antagonists. Indeed, modulation of glucocorticoid action is a key role of NF-κB (McKay & 
Cidlowski, 1999). In this way increased NF-κB activity, activated by stressors such as viral 
infection or oxidants (Baeuerle & Baltimore, 1996), and pro-inflammatory cytokines 
(DiDonato, Hayakawa, Rothwarf, Zandi, & Karin, 1997), may promote glucocorticoid 
resistance when chronically activated (e.g. Bantel, Schmitz, Raible, Gregor, & Schulze-
Osthoff, 2002).  
 Additional to this classical genomic signaling, feedback control of non-genomic 
immune signaling may be disrupted in transition to MDD, including cellular immunity. T and 
natural killer (NK) cell mediated immune responses are negatively regulated by 
glucocorticoids (Chen, Jondal, & Yakimchuk, 2017), and there is growing evidence that these 
cells (influencing neuro-inflammation and -protection) are involved in MDD development 
(Miller, 2010). Abnormalities in both cell levels and functions are evident in MDD (Blume, 
Douglas, & Evans, 2011; Eyre, Stuart, & Baune, 2014; Miller, 2010). There is general 
support for impaired Th2, Th17 and NK cell maturation with depressive state, and a fall in 
regulatory T cell numbers that correlates inversely with monocyte inflammatory state (Grosse 
et al., 2016a; Grosse et al., 2016b). Circulating T and NK cells might thus serve as useful 
biomarkers  - reduced regulatory T cell numbers in MDD are improved with anti-depressant 
therapy (though not necessarily predicting clinical outcome), whereas anti-depressant non-
responders exhibit elevated cytotoxic T and NK cell levels (Grosse et al., 2016a).  Abnormal 
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GR activity and glucocorticoid resistance may precipitate dysfunction in T cell maturation 
and function, worsening immune defense and risk of infection. Despite limited analyses in 
MDD, susceptibility to streptococcal infection is increased in children exposed to acute or 
chronic family stress (Meyer & Haggerty, 1962), low socioeconomic status increases 
respiratory infection in association with T cell telomere shortening (Cohen et al., 2013), and 
similar T cell senescence with early life adversity is linked to increased cytomegalovirus 
infection (Elwenspoek et al., 2017). T cells not only perform a surveillance function (Baruch 
& Schwartz, 2013), but regulate neurogenesis and neuroplasticity (Ziv & Schwartz, 2008), 
and protect against maladaptive behavioural responses (Lewitus et al., 2009). Removal of 
cortisol’s inhibitory effects with evolving glucocorticoid resistance may permit maladaptive 
T cell responses to emerge, promoting neurodegeneration (Toben & Baune, 2015). This may 
involve both elevated pro-inflammatory T cells and reduced regulatory T cells and anti-
inflammatory cytokines (Toben & Baune, 2015).   
In summary, dysregulation of both genomic and non-genomic GR signaling arises 
with chronic stress, contributing to glucocorticoid resistance and disrupting a fundamentally 
important negative feedback loop that normally dampens inflammation. This leads to 
dominance of pro- over anti-inflammatory cytokines and signaling, driving further GR 
disruption and glucocorticoid resistance, and further pro-inflammatory outcomes: previously 
negative feedback control has become disrupted to the point of shifting to a positive feed-
forward loop. This is illustrated in Figure 2B.  
 
2.1.3 Dysregulated Expression and Feedback Control of Glucocorticoid Receptors  
 At a deeper mechanistic level, expression and (dys)regulation of the GR itself governs 
glucocorticoid signaling and resistance, contributing to transitions from health to MDD, 
shown in Figure 2C. Stapelberg et al (2015) described the PINE network transition from 
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health to pathology in terms of a stress-diathesis model. While discussion of genetic and 
epigenetic mechanisms for all physiological pathways described here is beyond the scope of 
this paper, expression of GR is presented as an example. Certainly, unravelling these 
mechanisms and their integration into network models can clarify processes of immuno-
inflammatory dysregulation in transition to MDD, and reveal additional biomarkers of 
disease development and therapy. MDD is associated with declining expression of the GR 
gene (NR3C1) in the CNS (Webster, Knable, O'grady, Orthmann, & Weickert, 2002) and in 
circulating cells (Spindola et al., 2017), and with NR3C1 variant expression in females 
(Sarubin et al., 2017). However, the mechanisms orchestrating tissue-specific GR expression 
and levels of the 2 prevalent isoforms - dominant GRα involved in gene transactivation and 
inhibitory GRb - await further clarification (Turner et al., 2010). Increased GRb expression 
has been suggested as a mechanism for glucocorticoid resistance, though generally low level 
expression across cells argues against such a role (Pujols et al., 2003). However, nuclear 
shuttling of GRb via FK506 binding protein 51 (FKBP51) inhibits gene transactivation by 
active GRα shuttled via FKBP52 (Zhang, Clark, & Yorio, 2008). Thus, shifts in the 
FKBP51/52 rather than GRα/b ratio may be important in stress-dependent glucocorticoid 
resistance. This is consistent with associations between FKBP5 expression, glucocorticoid 
resistance and reduced coping behaviour, and FKBP5 gene variants and risk of affective 
disorders (Criado-Marrero et al., 2018). 
 These associations may reflect epigenetic control of GR and associated protein 
expression with chronic stress and MDD (Turner et al., 2010), though further work is needed 
to clarify these processes. It is increasingly clear NR3C1 together with BDNF and FKBP5 
promoters are hypermethylated in MDD patients, with concordant reductions in NR3C1 
genes and BDNF and shifts in FKBP5 variants (Roy, Shelton, & Dwivedi, 2017). Early life 
adversity, a major risk factor for psychopathology, is frequently associated with NR3C1 
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hypermethylation (Bustamante et al., 2016; Palma-Gudiel, Córdova-Palomera, Leza, & 
Fañanás, 2015). Childhood abuse (McGowan et al., 2009), parental loss (Tyrka, Price, 
Marsit, Walters, & Carpenter, 2012), and maternal depression (Oberlander et al., 2008) or 
separation (Weaver et al., 2004) are all associated with hypermethylation of a splice-variant 
promoter, which decreases total and NR3C1 1-F mRNAs (McGowan et al., 2009). The 
miRNA-dependent control of GR and FKBP expression may also be important in MDD, and 
warrants more extensive interrogation. For example, a miR-124 antagomir counters stress-
dependent depressive behaviours and activates BNDF (Wang et al., 2017), and depression-
like behaviour is associated with increased miR-124a and FKBP5 vs. reduced GR levels in 
the amygdala (Xu et al., 2017).  
 Post-translationally, GR signaling, feedback control and resistance are phospho-
regulated (Ismaili & Garabedian, 2004) (Figure 2C). Links between GR phosphorylation and 
negative affectivity support utility as a potential biomarker, and its incorporation into the 
molecular signature of negative affective states (Jovicic et al., 2015). Stress, glucocorticoids 
and inflammatory cytokines, together with growth factors, sex hormones and other kinase 
modulators, modulate GR phosphorylation within a N-terminal domain region linked to 
cofactor binding and gene transactivation (Anacker et al., 2011b; Guidotti et al., 2013)  
(Figure 2C). Genomic signaling is promoted by Ser203 or Ser211 phosphorylation, which 
enhances nuclear translocation and transactivation, while Ser226 phosphorylation increases 
nuclear export and degradation of GRs and inhibits transactivation (Anacker et al., 2013b; 
Guidotti et al., 2013; Ismaili & Garabedian, 2004). GR turnover is highly dependent on 
phosphorylation, with receptor half-life greatly augmented in the absence of this control 
(Webster et al., 1997).  
 GR phosphorylation is modulated by FKBP51 and 52, and mediated by kinases 
including cytokine-induced c-Jun N-terminal kinases (JNKs), p38-MAPK, cyclin-dependent 
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kinases (CDKs) and GR inducible serum- and glucocorticoid-inducible kinase 1 (SGK1) 
(Ismaili & Garabedian, 2004; Miller et al., 2005). The FK506 binding proteins 51 and 52 
(encoded by FKBP5 and 4) function with HSP90 as co-chaperones for inactive and active 
GRs, respectively (Criado-Marrero et al., 2018; Storer, Dickey, Galigniana, Rein, & Cox, 
2011; Wang, Frederick, & Garabedian, 2002), and are linked to MDD pathogenesis (Simic et 
al., 2013b; Tatro et al., 2009). Lacking direct phospho-regulatory properties, FKBP51 and 
FKBP52 influence phosphorylation via ill-defined mechanisms to inhibit and promote GR 
signaling, respectively. The balance of FKBP51 and 52 expression, which also determines 
shuttling of inhibitory GRb vs. active GRα isoforms, thus modulates GR activation, 
translocation and gene transactivation, with imbalances contributing to glucocorticoid 
resistance (Bourke et al., 2013; Guidotti et al., 2013). Conversely, Ser226 phosphorylation by 
JNK (Avenant, Kotitschke, & Hapgood, 2010; Chen et al., 2008; Itoh et al., 2002) or p38-
MAPK (Mercado et al., 2012) increases nuclear GR export and reduces transcriptional 
activity, while p38-dependent Ser203 phosphorylation may also maintain GRs in an inactive 
state (Bouazza et al., 2014). Other post-translational control is sensitive to phosphorylation: 
JNK-dependent phosphorylation at Ser246 (226 in human GRs) enhances sumoylation to 
suppress transactivation (Beck, De Bosscher, & Haegeman, 2011; Davies et al., 2008), and 
ligand-mediated proteasomal GR degradation requires phosphorylation-dependent lysine 
ubiquitination (Beck et al., 2011; Webster et al., 1997).  
Dephosphorylation is also altered with stress and inflammation. The 
dephosphorylation of GR serines 203, 211 and 226 may be mediated by PP5 (Bouazza et al., 
2012; Ismaili & Garabedian, 2004; Silverstein et al., 1997; Wang, Chen, Kono, Dang, & 
Garabedian, 2007), which also acts as co-chaperone with HSP90 in GR shuttling, and is 
induced on GR activation to reduce Ser211 phosphorylation and inhibit signaling (Bouazza et 
al., 2012) (Figure 2C). Down-regulating PP5 enhances GR phosphorylation and 
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transactivation (Bouazza et al., 2012), increasing gene expression without affecting GR 
binding (Zuo et al., 1999). Dephosphorylation of upstream kinases targeting the GR also 
inhibits GR phosphorylation, including JNK dephosphorylation via protein phosphate 2A, 
protein tyrosine or dual specificity protein phosphatase activities.  
The importance of phospho-regulation is reflected in the neuroplasticity effects of 
BNDF, dysregulation of which is implicated in MDD (Duman, Heninger, & Nestler, 1997; 
Hashimoto, 2013; Hashimoto, Shimizu, & Iyo, 2004). Neuroplasticity induced via the BNDF 
receptor (Trkb) involves essential GR phosphorylation and transactivation of plasticity genes 
(Arango-Lievano et al., 2015; Lambert et al., 2013), as does anti-depressant mediated 
neurogenesis (Anacker et al., 2011b). Neurogenesis outcomes may involve distinct effects of 
low sensitivity GRs vs. higher sensitivity MRs: normally low cortisol levels may act via MRs 
to increase hippocampal progenitor cell proliferation and differentiation into astrocytes, high 
cortisol levels inhibit proliferation via GRs, and combined GR and MR activities reduce 
neurogenesis into microtubule-associated protein 2-positive neurons and doublecortin-
positive neuroblasts (Anacker et al., 2013a). Impaired neurogenesis with chronic stress may 
thus involve inhibitory effects of combined MR/GR signaling (reduced MR/GR ratio), and 
increased GR phosphorylation via GR inducible SGK1 and other kinases (Anacker et al., 
2013b), leading to MR and GR desensitization and resistance (Holsboer, 2000). 
As outlined in Figure 2C, phospho-regulation of GRs thus involves a balance between 
stimulatory (eg. glucocorticoid, BDNF) and inhibitory (eg. inflammatory cytokine) pathways. 
Negative feedback control includes GR transactivation of kinase inhibitors (eg. CDK 
inhibitor proteins), upstream triggers of kinase pathways (eg. anti-inflammatory cytokines) 
(Anacker et al., 2011b), counter-regulatory phosphatase proteins (eg. PP5), and inhibitory 
FKBP51. With chronic stress and inflammation this balance is increasingly shifted towards 
inhibitory phosphorylation via JNK and p38-MAPK. Coupled with initial GR-dependent 
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induction of PP5, kinase inhibitors and FKBP51, these changes induce glucocorticoid 
resistance, opening the feedback loop to exaggerate inflammatory responses, impair 
neurogenesis and promote system transitions in the path to MDD. Elevated cortisol levels in 
MDD do correlate with GR Ser226 phosphorylation (Simic et al., 2013), and nuclear GR 
Ser226 phosphorylation correlates with depressive symptoms in females (not males) (Simic 
et al., 2013a). Increased FKBP5 gene and FKBP51 protein are also observed in MDD (Simic 
et al., 2013b; Tatro et al., 2009), with hippocampal levels elevated in animal stress models, 
though again in females and not males (Bourke et al., 2013). Such sexually dimorphic 
outcomes are congruent with sex-specificity of GR phospho-regulation (Brkic et al., 2017). 
For example, lipolysaccharide (LPS) induced sickness behaviour is associated with increased 
GR phosphorylation, nuclear translocation and FKBP expression in females vs. reductions in 
males. This is important in light of evidence variations in the GR gene (NR3C1) are linked to 
MDD in females but not males (Sarubin et al., 2017), collectively suggesting a more 
dominant role for GR signalling in females than males.  Sexual dimorphisms in MDD and 
underlying pathophysiology (Cosgrove, Mazure, & Staley, 2007; Goel, Workman, Lee, 
Innala, & Viau, 2014; Kessler, 2003; Nolen-Hoeksema, 1987) are a fundamentally important 
though complicating factor, just as existence of multiple MDD sub-types complicates 
interpretation and limits the utility of biomarkers. 
In summary, disruption of GR-available glucocorticoid levels, interactions between 
GR and NF-kB, and shifts in post-translational and epigenetic control of GRs lead to changes 
in both genomic and non-genomic signalling (all influenced in turn by genetic background), 
collectively underpinning glucocorticoid resistance and contributing to transition or reversals 
in feedback control (see Figure 2). This disruptive FLT impacts humoral and cellular 
immunity and increases levels of CNS inflammatory mediators, leading to what has been 
termed ‘sickness behavior’ (Dantzer, 2009; Dantzer, O'Connor, Freund, Johnson, & Kelley, 
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2008; Reichenberg et al., 2001), a behavioural response to infection or inflammation 
prompting conservation and redirection of energy for recovery. Symptoms include loss of 
appetite, lethargy and withdrawal from physical and social environments (Dantzer, 2009). 
These may reflect a normal and beneficial response to infection, an appropriate shift in 
behavioural priorities (Dantzer, 2009) such that the organism rests and recovers, rather than 
engaging in conflicting energy-demanding tasks. However, these also represent 
neurovegetative symptoms of MDD (Association, 2013), an overlap suggesting sickness 
behaviour is a subset of depressive symptomatology, driven by the low-grade pro-
inflammatory state apparent in MDD (Stapelberg et al., 2015). Dantzer (2009) argues that 
sickness behaviour can become pathological when occurring in the absence of an infective 
cause or when exaggerated in intensity or duration. This appears to be the case in MDD, with 
the mechanisms detailed above and the following descriptions of changes in gut biome and 
permeability and the kynurinine pathway providing examples of shifts in immuno-
inflammatory regulation from negative to positive feed-forward states. 
 
2.2 Immune-Related Feedback Loops: The Gut Microbiome and Gut Permeability 
Positive Feedback Loop 
The human digestive tract harbors a complex community of microorganisms 
comprising some 40000 species of bacteria (weighing between 1 and 2 kg) that provide 
important host benefits, including ability to break down indigestible dietary polysaccharides 
(Foster & Neufeld, 2013). There are tradeoffs in maintaining what is normally a beneficial 
symbiosis for host and microbiome: large quantities of bacteria must be kept in close 
proximity to a metabolic system that can be overwhelmed and destroyed by them. A balance 
is maintained by stratification (minimizing direct contact between gut microbiota and the 
epithelial cell surface) and compartmentalization (confining the microbiome to intestinal sites 
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that limit exposure to the systemic immune compartment) (Hooper, Littman, & Macpherson, 
2012). If gut microbiota, or associated microbial molecules such as LPS, do cross the gut 
wall and enter the blood, they stimulate an immune response which maintains 
compartmentalization. However, this control may be disrupted with excess or chronic 
passage of luminal LPS and other bacterial molecules across the gut wall (as a result of 
altered biome or permeability), transitioning to feed-forward control and promotion of pro-
inflammatory state. 
Raised blood concentrations of LPS have been linked to specific symptoms of MDD 
in animal models (e.g. Dantzer et al., 2008) and human studies (e.g. Wright, Strike, Brydon, 
& Steptoe, 2005). These symptoms include low energy and fatigue, loss of appetite, sleep 
disturbance, loss of sex drive and anhedonia, consistent with sickness behavior (Dantzer, 
2009; Dantzer et al., 2008; Reichenberg et al., 2001) and identical to neurovegetative 
symptoms and anhedonia observed in MDD (Dantzer, 2009; Stapelberg et al., 2015). 
Normally, the intestinal epithelial barrier (IEB) allows luminal fluid and nutrients to cross the 
intestinal wall while limiting passage of LPS and other bacterial products (Mass, Kubera, & 
Leunis, 2008). However, increased levels of pro-inflammatory cytokines (e.g. interferon-γ, 
IL-6) promote IEB permeability to large molecules such as LPS (Chavez, Menconi, Hodin, & 
Fink, 1999; Clark, Hoare, Tanianis-Hughes, Carlson, & Warhurst, 2005; Yang et al., 2003), 
with increased serum LPS promoting further pro-inflammatory cytokine release (Dantzer et 
al., 1999; Maes, Mihaylova, & Leunis, 2007). This in turn leads to further IEB 
permeabilization to LPS and other bacterial macromolecules, creating the positive feedback 
loop summarised in Figure 2B. The permeability of the IEB thus represents a critical node, or 
determinant of feedback control transition - beyond a permeability threshold, passage of 
bacterial molecules trigger a self-propagating pro-inflammatory response (inflammation-
dependent permeabilization drives up LPS levels, thus further inflammation and 
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permeabilization). This transition in feedback control (FLT) of barrier function is in turn 
related to transition in feedback within the 'HPA-gut axis'.  
CRH plays a key role in gut function, increasing motility and secretion (Taché & 
Bonaz, 2007). Increased gut motility can over time change the composition of the gut 
microbiome (Quigley, 2011), with biome changes impacting permeability (Tremaroli & 
Bäckhed, 2012), and thus circulating levels of LPS and molecules that up-regulate pro-
inflammatory mediators. These changes lead in turn to increased CRH levels, reflecting a 
positive feedback loop involving the gut microbiome. Thus, the composition of the gut 
microbiome, determining IEB permeability, is a key determinant of regulatory transitions and 
contributes to a system-wide critical transition to MDD. Feedback loop transition is further 
promoted by the effects bacterial toxins on glucocorticoid resistance, impairing GR function 
and GR transactivation (Silverman & Sternberg, 2012). Since glucocorticoid resistance 
increases CRH secretion, reflecting loss of negative feedback control, transitions in feedback 
control of glucocorticoid signalling, gut biome and permeability potentiate each other, 
arguably driving positive feedback loop dominance and critical transition to MDD. 
  
2.3 Immune-Related Feedback Loops: The Kynurinine Pathway Negative Feedback 
Loop and the Astrocyte-Microglia Ratio 
High systemic levels of pro-inflammatory cytokines can induce a pro-inflammatory 
milieu within the CNS. The kynurinine pathway (KP) is central to immune modulation 
throughout the body, including the CNS where the pathway is facilitated by microglia. The 
KP is implicated in negative feedback control of inflammation, responding to pro-
inflammatory state and inhibiting inflammation via its metabolites. However, the ratio of KP 
metabolites in the CNS can be altered with chronic stress to ultimately promote pro-
inflammatory changes, transitioning to an abnormal positive feedback loop. With chronic 
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stress, a pro-inflammatory milieu in the CNS disrupts glial populations, resulting in 
predominance of microglia and depletion of astrocytes (reviewed in Stapelberg et al., 2015). 
This amplifies the KP positive feedback loop, which has multiple effects, including 
disruption of CNS serotonergic function and neural health, and inhibition of hippocampal 
neurogenesis, all precursors to MDD. 
Microglia are critical in functionally supporting the central KP (Müller & Schwarz, 
2007). Microglia produce indoleamine 2,3-dioxygenase (IDO) which converts tryptophan to 
kynurenine (McNally, Bhagwagar, & Hannestad, 2008; Müller & Schwarz, 2007). The 
activity of IDO, thus of the KP itself, is stimulated by pro-inflammatory cytokines such as 
interferon-γ, TNF-α, IL-1 and IL-2 (reviewed in Mándi & Vécsei, 2012). As shown in Figure 
3A, kynurenine is further converted to kynurenic acid and 3-hydroxykynurenine, with the 
latter converted to quinolinic acid (Müller & Schwarz, 2007).  
 
[Figure 3A could be placed here] 
 
The KP and its metabolites are important in the balance between neurotoxicity and 
neuroprotection in the CNS (Allison & Ditor, 2014). Kynurenic acid dampens inflammation 
by inhibiting production of the key mediator TNF-α (Mándi & Vécsei, 2012). The inhibition 
of TNF-α production has a neuroprotective function, as TNF-α provokes glutamate-
induced neuronal cell death (Zou & Crews, 2005) and neuronal death with stroke and other 
CNS insults. Kynurenic acid acts as an NMDA antagonist (Stone & Perkins, 1981), blocking 
TNF-α potentiation of glutamate neurotoxicity (Zou & Crews, 2005). Other KP metabolites, 
such as 3-hydroxykynurenine and quinolinic acid, have neurotoxic effects. For example, 
quinolinic acid acts as a selective NMDA receptor agonist, driving glutamate-mediated 
neurotoxicity (Stone & Perkins, 1981) and thus functionally opposing the effects of 
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kynurenic acid itself. The balance between kynurenine transamination to kynurenic acid vs. 
hydroxylation and subsequent metabolism to quinolinic acid is thus a determinant of 
neurotoxicity, as is the overall activity of the KP (governed by the rate-limiting enzymes IDO 
and TDO).   
Chronic stress drives increased KP activity via elevated pro-inflammatory cytokine 
levels, increasing the quinolinic acid to kynurenic acid ratio and thus cytotoxic NMDA 
agonism (Fedele & Foster, 1993; Myint et al., 2007). In addition, quinolinic acid itself is 
neurotoxic, thus excess KP activity can directly induce neuronal damage (Müller & Schwarz, 
2007). Increased glutamate activity in turn stimulates TNF-α release from activated microglia 
(Pocock & Kettenmann, 2007). A prolonged pro-inflammatory state in the CNS can therefore 
transition negative feedback control to a positive feedback (feed-forward) loop wherein 
microglia are activated and stimulate the KP, with KP metabolites promoting inflammatory 
activation via a shift in the balance of glutamate receptor agonism vs. antagonism (McNally 
et al., 2008). This FLT within the KP hinges on the cumulative activity of IDO (a sentinel 
network node), which in turn determines the quinolinic acid to kynurenic acid ratio, as shown 
in Figure 3A. 
Additional exacerbation of the KP positive feedback loop arises over time as the 
cytotoxic effects of the KP reduce CNS astrocytes while microglial populations increase. 
Astrocytes have important protective functions (reviewed in Stapelberg et al., 2015), 
including secretion of neurotrophic factors such as neurotrophin-3, glial-derived neurotrophic 
factor and brain-derived neurotrophic factor (BDNF) (Connor & Dragunow, 1998; Cotter, 
Mackay, Landau, Kerwin, & Everall, 2001), and uptake of excess glutamate (McNally et al., 
2008) to limit the neurotoxicity induced by excess levels of this neurotransmitter (Bezzi et 
al., 2004; Furuta et al., 2005).  
These positive feedback motifs leading to MDD are shown in Figure 3B. With 
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declining CNS astrocyte populations due to excess KP activation, levels of BDNF are 
reduced and glutamate levels and neurotoxic KP metabolites accumulate. This in turn can 
lead to neuronal damage and impaired hippocampal neurogenesis, key mechanisms 
implicated in MDD (Pittenger, Sanacora, & Krystal, 2007; Sahay & Hen, 2008; Yirmiya & 
Goshen, 2011). In addition, the KP plays an important role in regulating overall tryptophan 
availability in the CNS (Mándi & Vécsei, 2012), thus also determining serotonin (5-HT) 
synthesis, as tryptophan availability is rate-limiting (Grohmann, Fallarino, & Puccetti, 2003). 
The KP shunts tryptophan away from 5-HT generation, which is thought to be a key 
mechanism in MDD (Müller & Schwarz, 2007; Stapelberg et al., 2015). Increased activity of 
the KP is linked to the cognitive deficits in MDD, for example (Allison & Ditor, 2014).  
 
[Figure 3B could be placed here] 
 
2.4 Autonomic Feedback Loops: The Sympathetic and Parasympathetic Negative 
Feedback Loop 
The sympathetic and parasympathetic divisions of the autonomic nervous system 
coexist in a state of dynamic antagonism throughout the body, maintaining a dynamic 
equilibrium. The parasympathetic nervous system is principally comprised of the vagal nerve 
system, thus parasympathetic activity is frequently referred to as vagal tone (Laborde, 
Mosley, & Thayer, 2017). Vagal function is an important homeostatic mediator in energy 
regulation and physiological processes including immuno-inflammatory function. Overall 
autonomic control is also achieved by vagal tone acting antagonistically to sympathetic drive 
(e.g. Porges, Doussard-Roosevelt, Portales, & Greenspan, 1996). Porges et al. (1996) have 
described the ‘vagal brake’ - the active increase in vagal tone to inhibit sympathetic action, 
and conversely the reduction in vagal tone that enables increased sympathetic drive when 
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required. 
Feedback exists between vagal and immuno-inflammatory functions, with vagal tone 
stimulated by immuno-inflammatory mediators, and in turn inhibits immuno-inflammatory 
activation. The role of the vagus in rapidly damping inflammatory responses has been termed 
the inflammatory reflex (Tracey, 2002), and highlights the importance of vagal function in 
regulating inflammatory mediators. Vagal activity triggers local release of acetylcholine 
(ACh), which directly inhibits release of pro-inflammatory cytokines and also indirectly 
suppresses their expression via stimulation of CRH secretion (Oke & Tracey, 2009).  
Approximately 80% of vagal nerve fibres are sensory and the vagus is stimulated by 
pro-inflammatory cytokines (Olofsson et al., 2012; Thayer, 2009), allowing subsequent 
dampening of peripheral inflammation. A localized infection, for example, triggers a local 
immune response and induces vagal stimulation. This vagal stimulus inhibits pro-
inflammatory cytokine release peripherally, creating a negative feedback loop that ensure the 
immune response is sufficiently dampened and localized, avoiding excessive tissue damage 
(Eskandari & Sternberg, 2002; Olofsson et al., 2012). This is shown in Figure 2A. 
However, vagal tone is compromised by chronic stress, with abnormally reduced 
vagal tone or vagal dysfunction a key feature and potential causal factor in MDD 
(Rottenberg, 2007; Stapelberg, Hamilton-Craig, Neumann, Shum, & McConnell, 2012). A 
reduction in vagal tone impairs the functionality of the ‘vagal brake’, leading to increased 
sympathetic drive that is also characteristic of MDD (reviewed in Stapelberg et al., 2011; 
Stapelberg et al., 2015). Over time, a loss of vagal tone leads to chronically elevated pro-
inflammatory cytokines, in turn driving dysfunction in inter-related immune, endocrine, CNS 
and gut systems. Loss of vagal tone also leads to chronically increased sympathetic drive. In 
the short term, sympathetic activation prepares the body for flight or flight via secretion of 
adrenaline and noradrenaline. However, chronic sympathetic drive can lead to pathologies 
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such as hypertension, blood coagulopathy and cardiac hypertrophy (reviewed in Stapelberg et 
al., 2015). The transition from vagal function to dysfunction with chronic stress thus 
represents a key FLT within autonomic control that broadly impacts other physiological 
systems. 
 
3. Discussion 
3.1 From FLTs to Critical Transition of the PINE Network - The Tipping Point To 
MDD 
 
Recent large-throughput genetic studies have focussed on the question of how cells, 
which are subject to large numbers of complex genetic and other multi-molecular 
interactions, can select specific pathways or cell fates, such as differentiation or immune 
responses, from the multiplicity of combinatorial possibilities (e.g. Huang, Eichler, Bar-Yam, 
& Ingber, 2005; Tsuchiya, Giuliani, Hashimoto, Erenpreisa, & Yoshikawa, 2015). Cellular 
processes are governed by system attractor sets, which cause systems to converge toward a 
minimal energy state, drawing multiple multi-molecular interactions into a stable state 
(Tsuchiya et al., 2015). However, there also exists the possibility of an entire system, such as 
a cell, or network of regulatory physiological interactions in the body (e.g. PINE network), 
being pushed towards a tipping point (Scheffer et al., 2009), where the system then undergoes 
critical transition, following another attractor set into a new stable yet distinct state (e.g. 
Huang et al., 2005). Critical transitions can be driven by self-organized criticality (Tsuchiya 
et al., 2015). Importantly, the emergence of a convergent system solution, governed by the 
attractor set that influences system dynamics over a given timespan, overcomes the stochastic 
fluctuations that might otherwise disrupt large-scale coherent functioning of a physiological 
system (Tsuchiya et al., 2015). 
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System attractor sets are emergent properties of complex systems, underpinned by the 
structural organisation of constituent (e.g. physiological) networks, but largely independent 
of the individual pathways of those networks (e.g. Mikulecky, 2001). It can be argued that a 
system such as the PINE network can be viewed as a single dynamical system without 
examining the specific physiological role of each node in the network. The behaviours of 
components within such a system can collectively contribute to a ‘global’ critical transition - 
collective FLTs in physiological sub-systems of the PINE network may collectively drive the 
PINE network to a critical transition from health to MDD through altered feedback loop 
dominance (see Ford, 1999; Sterman, 2000). It is thus important to identify possible FLTs 
and SNNs which may contribute to a critical transition to MDD.  
 
3.2 Use of Biomarkers to Predict Critical Transition to MDD 
The physiological transitions brought about by chronic stress and which ultimately 
manifest as MDD are reliant on the disruption of negative feedback loops that are normally 
involved in homeostasis. We have detailed how FLTs can result in the emergence of 
pathophysiological positive feedback loops which drive abnormal elevations in CRH, 
cortisol, pro-inflammatory cytokines and potentially damaging products of the KP. The 
effects of these mediators cascade, disrupting the normal function of multiple systems, for 
example promoting a sympathetically driven autonomic state or disrupting glial support 
functions in the CNS, ultimately resulting in a critical transition to MDD. It is also evident 
that most of the feedback loops described are intertwined, potentiating their disruptive 
capacities.  
The emergence of a critical system transition from health to disease, promoted by key 
inter-related FLTs, will be presaged by characteristic features of network instability. 
Complex systems exhibit early warning signs as they approach critical transitions, which can 
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be predictive within such systems (e.g. Scheffer et al., 2009). These early warning signs 
include ‘critical slowing down’ that can be measured by assessing recovery from 
perturbations; autocorrelation and an increase in variance; as well as an asymmetry of 
fluctuations characterized by so-called skewness and flickering (Scheffer et al., 2009). While 
critical transition of the entire PINE network to MDD is suggested to occur, instability of the 
network is hypothesised to arise in its regulatory subsystems, i.e. in the feedback loops 
described. Thus, we hypothesise that assessing early warning signs within feedback loops in 
the PINE network could theoretically predict the critical transition to MDD – possibly 
yielding clinical screening investigations for MDD. 
Firstly, as a system approaches a critical transition, it becomes increasingly slow at 
recovering from small perturbations. Recovery rates from a small perturbation decrease 
smoothly to zero as the system approaches critical transition (Van Nes & Scheffer, 2007). 
One example for a method for measuring slower recovery from perturbations in the PINE 
network would be to assess leukocyte 5-HT1A receptor expression over time. In depressed 
people, as compared with controls, 5-HT1A receptor expression on white blood cells is 
inversely correlated with 5-HT activity in plasma, low platelet density, and 5-
hydroxyindoleacetic acid (5-HIAA) as the excretory end-product of 5-HT metabolism. This 
occurs through a negative feedback mechanism affecting the HPA axis (Zhang et al., 2014). 
Resistance to change is described by the second derivative differential, where the rate of 
change in concentration of a biomarker is measured. Practically, this would require multiple 
measurements, which can be clinically untenable. However, leukocyte responses to the 
alterations in the rate of change can be measured. In this case, resistance to negative feedback 
inhibition and down-regulation of receptor expression is a biomarker reflecting the effect of 
changes in the velocity of 5HT1A concentration pathophysiologically. 
A second marker of critical transition is autocorrelation in patterns of fluctuation 
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within the system: autocorrelation is the repetition of a pattern over time (i.e. similarity 
between elements of a time series). In systems approaching a critical transition, increased 
autocorrelation is evident (Scheffer et al., 2009). It can be positive or negative, where there is 
increasing or decreasing amplitude of episodes of flickering or variance, respectively. For 
screening purposes, positive autocorrelation indicates that resistance to change has occurred 
and the biological system under analysis has changed from a negative feedback controlled 
system to one showing impaired control and markedly changed response to stimuli.  
IL-10 is an anti-inflammatory cytokine (Oral et al., 2006), in contrast to IL-6 which is 
both a pro-inflammatory cytokine (Heinrich et al., 2003) and anti-inflammatory myokine 
(Pedersen & Febbraio, 2008). These mediators have roles in modulating neuronal plasticity 
(Vidal, Lemmens, Dooley, & Hendrix, 2013). Sickness behaviour, including malaise, 
pyrexia, social isolation, anhedonia, anorexia, loss of concentration and lethargy, has been 
shown to be mediated by pro-inflammatory cytokines (Dantzer, 2009). Meta-analysis 
confirms elevations in IL-6 and TNFα in depressed patients (Dowlati et al., 2010). Cytokines 
are also related to low mood in males (Chen, Lin, Chen, Mao, & Hung, 2010). Measuring IL-
6 and -10 levels at different times may reveal a shift from a balanced inflammatory state 
(normal predominance of anti-inflammatory activity) to a pro-inflammatory state with 
elevations in pro-inflammatory biomarkers. It is suggested the ratio of IL-6 to IL-10 may 
change with an approaching critical transition to MDD. A ratio may detect such change. 
Thus, repeated IL-6/IL-10 ratio measures may flag a critical transition, revealing a change to 
a pro-inflammatory state through positive autocorrelation.  
Third, systems approaching critical transition display increased variance in the pattern 
of fluctuations of state variables (Carpenter & Brock, 2006). Such variance could be reflected 
in early warning biomarkers around FLTs in the PINE network. An example of a biomarker 
which might reflect increased variance is HbA1c, with measurement of the area under the 
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curve, or integral of the average plasma glucose over the preceding 8-12 weeks, if red blood 
cell survival is normal. In a HbA1c measure, approximately 50% is derived from the last 
month and the remainder from the remaining 2 months prior to testing (Sawyer, 2015). 
Insulin resistance or impaired glucose tolerance, as defined by oral glucose tolerance test, 
fasting plasma glucose or haemoglobin A1c,  has been clearly linked to depression (Winokur, 
Maislin, Phillips, & Amsterdam, 1988). 
Increased variance is evident when the range of concentrations of glycated 
haemoglobin measured over time increases above baseline. This indicates that plasma 
glucose concentration is at times elevated above the normal physiologically controlled range. 
This variance may not be detected by measuring random plasma glucose levels as changes 
can be transitory, though irreversible non-enzymatic binding of glucose to the N-terminal 
valine amino acid on the beta globin chains on haemoglobin A occurs directly in proportion 
to plasma glucose concentration, providing a historic measure. As it forms a stable ketoamine 
over the life of the red cell, the concentration of glycated HbA1c measures those elevations. 
It also measures the increased variance in the plasma glucose in the area under the curve of 
plasma glucose concentrations over the life of that red cell.  
Skewness and flickering are measures of increasing asymmetry of fluctuations before 
a critical transition (Scheffer et al., 2009). Skewness is a measure of the changing asymmetry 
of a time series probability distribution (i.e. skewness in the distribution of smaller state 
changes before a critical transition), which can be predictive of a critical transition (Guttal & 
Jayaprakash, 2008). Flickering is a related phenomenon, where a system oscillates back and 
forth between two opposing system basins of attraction, entering a bi-stable state before 
undergoing a critical transition to a single new stable state (Berglund & Gentz, 2002).  
Skewness might be measured by assaying anti-thyroperoxidase (anti-TPO) antibodies, 
where skewness from baseline over time is the first derivative differential revealed by an 
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increase in anti-TPO antibodies. An increase in anti-TPO and anti-TSH receptor antibodies 
reveals skew from baseline over time and is the first derivative differential or change in 
concentration divided by change in time. A higher lifetime prevalence of depression is 
observed in anti-TPO antibody positive vs. negative individuals (Dufour, 2007), with a 
reported association between anti-TPO antibodies and lifetime diagnosis for MDD (Carta et 
al., 2004). Increased levels of anti-TPO antibodies suggests they might be used as a trait 
biomarker in MDD (van de Ven et al., 2012), and are associated with concurrent telomere 
shortening (Ridout, Ridout, Price, Sen, & Tyrka, 2016) suggesting recent epigenetic changes. 
Anti-TPO antibodies are also associated with increased risk of hypothyroidism, a known 
cause of MDD (Fountoulakis, Iacovides, Grammaticos, St Kaprinis, & Bech, 2004; 
Marangell & Callahan, 1998). Taken together, this suggests that skew above baseline in anti-
TPO antibodies might be a useful clinical biomarker (within a profile) in screening for MDD.  
Finally, flickering is a measure of increasing asymmetry of fluctuations over time 
before a critical transition, which can theoretically be captured using heart rate variability 
(HRV). HRV has been established as a measure of autonomic cardiac control (or cardiac 
vagal control) (Rottenberg, 2007) and is believed to reflect autonomic function (NASPE, 
1996). However, HRV measures can reflect multiple complex physiological processes 
simultaneously (e.g. spectral HRV measures), which has challenged assertions of HRV being 
a direct or simple biomarker of autonomic function (e.g. Grossman & Taylor, 2007). Cardiac 
beat-to-beat time series are inhomogeneous, non-stationary, and fluctuate in an irregular and 
complex manner, making them suitable for non-linear measures of HRV (e.g. Ivanov et al., 
2001). Systems embedded in stochastic environments may start to ‘flicker’ between basins of 
attraction for potentially alternative states before a critical transition (Dakos, van Nes, & 
Scheffer, 2013). Flickering could theoretically be investigated in the time series of 
consecutive R-wave intervals in a 24 hour cardiac recording, which may be indicative of a 
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critical transition in people with chronic stress that may precede MDD. Cardiac dynamics can 
shift between alternate states, governed by different attractors, and the complex patterns of 
cardiac activity which result are observable (e.g. Lerma, Krogh-Madsen, Guevara, & Glass, 
2007). Application of a methodology which detects flickering might thus predict critical 
transitions due to underlying changes in autonomic function. Jump-drift-diffusion algorithms 
(Dakos et al., 2013) could be applied to the time series of consecutive R-wave intervals in a 
24 hour cardiac recording. For example, Zheng, Skufca, and Bollt (2013) used the low 
frequency component of RR-interval data to analyse the stochastic jump with persistence 
around a bifurcation point, which relates to sympathetic and parasympathetic cardiac control 
and it is proposed that similar methodology could be used to detect a critical transition to 
MDD.   
In summary, in progressing from one stable state to another, a system will undergo a 
period of instability. This instability has discernible and measurable patterns, including 
measures of critical slowing down, autocorrelation and increased variance, skewness and 
flickering in physiological regulatory systems. Critical slowing has been demonstrated in 
MDD in the context of fluctuations of emotional state, supporting the validity of this 
approach. Van de Leemput and colleagues (2014) demonstrated that elevated temporal 
autocorrelation, variance, and correlation between emotions in fluctuations of auto-recorded 
emotions were related to an increased probability of a shift between a normal mood state and 
MDD. The authors concluded that mood may have alternative stable states separated by 
critical transitions. We propose that the critical transition from the PINE physiome to the 
pathophysiological state of MDD (the PINE pathome) involves a series of FLTs and similar 
emergence of an intermediate unstable state (presented in Figures 2 and 3). Detection of 
FLTs and characteristic biomarkers of evolving instability can thus predict critical transition 
of the entire PINE network. We propose that the biomarker examples above be considered as 
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a linked network, reflecting interactions between feedback systems described in this paper. 
While changes in each biomarker could theoretically be monitored in isolation, there is 
additional benefit if viewed in the context of a network of biomarkers. These and other 
biomarkers could be used together as a suite of screening measures for MDD, detecting 
patterns such as temporal autocorrelation, variance or flickering before MDD sets in.  
 
3.2 Limitations and Recommendations 
Both the network model and the biomarkers presented here are putative and require 
experimental confirmation. This paper has sought to provide a testable hypothesis in terms of 
biomarkers in relation to PINE network FLTs, which might be used as a screening test for 
progression towards MDD. It is recommended that future work focus on testing the 
hypothesis that identification of key network motifs relating to feedback loops presents a list 
of biomarker candidates which can predict the onset of MDD in vulnerable (e.g. chronically 
stressed) individuals.  
Furthermore, the model of feedback loops presented here is not necessarily complete, 
but serves rather to provide examples of FLTs which could drive a shift of the PINE network 
from health, through a pre-disease state followed by critical transition to the alternate stable 
state of MDD. Further work is required to fully map the metabolome relevant to chronic 
stress and MDD, and it is likely that many additional feedback loops will be identified. This 
paper presents concepts and a basic model which we hope that others will use as a starting 
point to mathematically model the PINE network. The behaviour of the whole network is 
likely to be more complex, especially when interactions within it are viewed over time. Such 
a model would require a more extensive understanding of the PINE network, statistical 
estimation of the governing parameters of the model and should be informed by experimental 
data. 
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There is a need to identify and map similar network motifs which extend across 
multiple networks (or fields of study), such as transcriptomics, proteomics and connectomics. 
For example, it is possible that some individuals may have a genetic predisposition which 
makes it easier for chronic stress to produce glucocorticoid resistance. This in turn may lead 
to collapse of negative feedback loops earlier or with lower stress thresholds in predisposed 
individuals. In a further example, TNF-α gene polymorphisms may have a role in MDD 
susceptibility, with depressed people having an increased frequency of the TNF2 (A) allele 
(Jun et al., 2003). Such predisposition may mean that pro-inflammatory states involving 
TNF-α are reached earlier or more readily, and also supports the stress diathesis model of 
MDD. Further work should reconcile such feedback loops across different network levels, 
with specific reference to mental disorders such as MDD and the effect on FLTs in the PINE 
network. 
 Multiple moderating factors may also influence the PINE network and potential 
FLTs. For example, age, sex and genetic makeup all influence responses to stress (Bekhbat & 
Neigh, 2017; Novais, Monteiro, Roque, Correia-Neves, & Sousa, 2017). Age has been 
previously discussed as a moderator in the context of the PINE network (Stapelberg et al., 
2015). Gender is another important moderator, and the physiology of MDD, in terms of 
metabolic pathways and gender-sensitive hormone effects, may be different in men and 
women. Men and women exhibit differing incidences and symptoms of depression, and 
responses to antidepressant medication (Altemus, Sarvaiya, & Epperson, 2014; Keers & 
Aitchison, 2010; Parker & Brotchie, 2010; Sramek, Murphy, & Cutler, 2016), changes 
mirrored to some degree by studies in animal models (Dalla, Pitychoutis, Kokras, & 
Papadopoulou-Daifoti, 2010; Kokras & Dalla, 2017). It is thus possible that some FLTs will 
be sensitive to age and gender, which should be the subject of further investigation. Maternal 
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influences are an additional modifier, with pre-natal stress and depression known to alter 
stress responses, resilience and depression in adult offspring (van Bodegom, Homberg, & 
Henckens, 2017; Van den Bergh et al., 2017), and childhood adversity also influencing HPA 
axis function, stress responses and disease propensity later in life (Berens, Jensen, & Nelson, 
2017; van Bodegom et al., 2017). 
Lastly, recent work supports the clustering of MDD into distinct subtypes, based on 
latent class analysis (Lamers et al., 2010), including melancholic depression and atypical 
depression. These two subtypes have also been shown to have different underlying 
physiology, e.g. decreased HPA axis activity but increased pro-inflammatory activity in 
people with the atypical depressive subtype (compared to non-depressed controls), and 
greater HPA-axis hyperactivity and less pro-inflammatory marker activity associated with the 
melancholic subtype (Lamers et al., 2013). We speculate that the principles outlined in this 
paper around physiological FLTs are applicable to both melancholic and atypical subtypes, 
though the detailed physiology may be different. Further work is required to delineate these 
differences and further characterize the physiological networks underlying these depressive 
subtypes, as well as their physiological feedback loops.   
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Figures 
Figure 1: Relationships between feedback loops, loop dominance and critical transitions in a 
complex biological system progressing from health to a disease state 
Figure 2A: Interlinked feedback loops involving endocrine, autonomic and gut microbiome 
pathways in the psycho-immune-neuroendocrine network during normal homeostasis 
Figure 2B: Progression from negative to positive feedback loops involving endocrine, 
autonomic and gut microbiome pathways in the psycho-immune-neuroendocrine network 
Figure 2C: Progression from negative feedback loop control of GR phosphorylation and 
function 
Figure 3A: Interlinked feedback loops involving the kynurenine pathway in the psycho-
immune-neuroendocrine network during normal homeostasis 
Figure 3B: Progression from negative to positive feedback loops involving the kynurenine 
pathway in the psycho-immune-neuroendocrine network 
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